HomeCompareBTSDF vs ABBV

BTSDF vs ABBV: Dividend Comparison 2026

BTSDF yields 1.94% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $84.7K in total portfolio value
10 years
BTSDF
BTSDF
● Live price
1.94%
Share price
$1.59
Annual div
$0.03
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$0.19
Full BTSDF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — BTSDF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBTSDFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BTSDF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BTSDF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BTSDF
Annual income on $10K today (after 15% tax)
$164.59/yr
After 10yr DRIP, annual income (after tax)
$0.16/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,866.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BTSDF + ABBV for your $10,000?

BTSDF: 50%ABBV: 50%
100% ABBV50/50100% BTSDF
Portfolio after 10yr
$62.4K
Annual income
$12,862.96/yr
Blended yield
20.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BTSDF
No analyst data
Altman Z
2.3
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BTSDF buys
0
ABBV buys
0
No recent congressional trades found for BTSDF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBTSDFABBV
Forward yield1.94%3.12%
Annual dividend / share$0.03$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$20.0K$104.7K
Annual income after 10y$0.19$25,725.73
Total dividends collected$195.00$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BTSDF vs ABBV ($10,000, DRIP)

YearBTSDF PortfolioBTSDF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,797$96.82$11,559$438.51$762.00ABBV
2$11,601$48.85$13,494$640.86$1.9KABBV
3$12,438$24.53$15,951$945.97$3.5KABBV
4$13,321$12.29$19,152$1,413.89$5.8KABBV
5$14,260$6.15$23,443$2,146.38$9.2KABBV
6$15,261$3.08$29,391$3,321.96$14.1KABBV
7$16,331$1.54$37,948$5,265.87$21.6KABBV
8$17,475$0.77$50,795$8,596.74$33.3KABBV
9$18,698$0.38$71,034$14,549.41$52.3KABBV
10$20,007$0.19$104,715$25,725.73$84.7KABBV

BTSDF vs ABBV: Complete Analysis 2026

BTSDFStock

Health and Happiness (H&H) International Holdings Limited, an investment holding company, manufactures and sells family nutrition and baby care products worldwide. The company's Infant Formulas segment produces infant formulas for children under seven years old and milk formulas for expectant and nursing mothers. Its Probiotic Supplements segment offers probiotic supplements in the form of sachets, capsules, and tablets for infants, children, and expectant mothers. The company's Adult Nutrition and Care Products segment produces vitamins, health supplements, and skincare and sports nutrition products for adults. Its Other Pediatric Products segment produces dried baby food and nutrition supplements, and baby care products. The company's Pet Nutrition and Care products segment produces food, health supplements, and bone broth products for pets. It is also involved in the research, development, and processing of meat, fruit, and vegetable powder and candy; research, development, manufacture, and sale of special nutritional foods; marketing and distribution of organic baby foods; and wholesale, retail, import, and export of nutritional food and personal care products for infants. In addition, the company engages in the trading and sale of vitamins, health supplements, probiotic skin care, and sports nutrition products for adults; and provision of online sales, software, and information technology services, as well as packaging services. It provides its products under the Biostime, Swisse, Aurelia, Zesty Paws, Solid Gold, Dodie, Good Gout, Aurelia London, and CBII brands. The company was formerly known as Biostime International Holdings Limited and changed its name to Health and Happiness (H&H) International Holdings Limited in June 2017. The company was founded in 1999 and is headquartered in Quarry Bay, Hong Kong. Health and Happiness (H&H) International Holdings Limited is a subsidiary of Biostime Pharmaceuticals (China) Limited.

Full BTSDF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BTSDF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BTSDF vs SCHDBTSDF vs JEPIBTSDF vs OBTSDF vs KOBTSDF vs MAINBTSDF vs JNJBTSDF vs MRKBTSDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.